WANY
JAZZ icon

Wealthspire Advisors (New York)’s Jazz Pharmaceuticals JAZZ Stock Holding History

Wealthspire Advisors (New York)’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-521
Closed -$68.7K – 1977
2025
Q3 		$68.7K Buy
+521
New +$62.5K ﹤0.01% 1130

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Wealthspire Advisors (New York)'s JAZZ Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2025, closing a stake of 521 shares — an estimated $68.7K sold.

Wealthspire Advisors (New York) first reported a position in JAZZ in Q3 2025 and held it in 1 quarter. The position peaked at $68.7K in Q3 2025. 573 funds tracked by Wall St. Rank hold JAZZ as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Jazz Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 521 Jazz Pharmaceuticals shares in Q4 2025, an estimated $68.7K.
  • Wealthspire Advisors (New York) first reported a position in Jazz Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Jazz Pharmaceuticals position peaked at $68.7K in Q3 2025.
  • 573 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.